# Irritable Bowel Syndrome

Use a positive symptom-based diagnosis, screen selectively for inflammatory, celiac, infectious, and structural mimics, then match therapy to bowel pattern and dominant symptom while reassessing alarm features or treatment-resistant change.

**Clinical question:** How should clinicians diagnose IBS efficiently, exclude consequential mimics, and select treatment by stool subtype and dominant symptom?

Updated: 2026-08-24T17:28:16.168507+00:00

## What matters in practice
- Make a positive IBS diagnosis using Rome IV symptoms and Bristol stool pattern; do not pursue exhaustive exclusion testing when alarm features are absent. [7][11][14]
- For suspected IBS-D, obtain tissue transglutaminase IgA with total IgA and use CRP plus fecal calprotectin or lactoferrin to evaluate for celiac disease and inflammatory bowel disease. [11][14]
- Treat the dominant symptom and subtype: soluble fiber, antispasmodics or peppermint oil for pain; laxative-based therapy and linaclotide for refractory IBS-C; loperamide for diarrhea, with rifaximin and selected 5-HT3-directed therapy for persistent IBS-D. [4][7][19]
- New onset after midlife, bleeding, unexplained iron-deficiency anemia, weight loss, nocturnal symptoms, or a relevant family history should redirect evaluation toward organic disease rather than empiric IBS escalation. [11][14][22]

## When to diagnose IBS without extensive testing

Confirm the symptom pattern, identify stool subtype, and screen immediately for features that alter the pathway.

Diagnose IBS clinically when recurrent abdominal pain occurs at least 1 day per week and is associated with defecation and/or a change in stool frequency or form. Classify subtype with the Bristol Stool Form Scale: IBS-D has more than 25% of bowel movements with loose or watery stools, while IBS-C, IBS-M, and IBS-U require subtype assignment from the prevailing stool pattern. Use the same scale longitudinally to document treatment response or subtype shift. [11][14][18]

A symptom-based diagnosis is appropriate when the examination is unrevealing and alarm features are absent; in patients meeting Rome IV criteria for IBS-D without alarm features, symptom-based diagnosis has been reported as accurate in up to 98% of cases. Avoid broad food-allergy or food-sensitivity panels; reserve allergy evaluation for rapid, reproducible reactions that resolve with avoidance and are clinically compatible with food allergy. [11]

At each initial or reassessment visit, ask specifically about rectal bleeding, unintentional weight loss, unexplained iron-deficiency anemia, nocturnal symptoms, new onset after age 45 to 50 years, acute unexplained symptom change, and a first-degree family history of colorectal cancer, inflammatory bowel disease, celiac disease, or significant gastrointestinal disease. These findings require evaluation for an organic disorder rather than labeling symptoms as uncomplicated IBS. [11][14][22]
- Document abdominal pain frequency, its relationship to defecation, stool frequency, and Bristol form before initiating subtype-directed treatment. [11][14]
- Perform a focused abdominal examination and digital rectal examination when anorectal disease, bleeding, evacuation disorder, or another structural explanation is plausible. [10]
- Reopen the differential when a previously stable IBS phenotype develops persistent bleeding, anemia, weight loss, nocturnal symptoms, or a substantial bowel-habit change. [11][14]

*Clinical features that determine whether to follow a limited IBS workup or pursue an organic-disease evaluation. [11][14][22]*

| Clinical finding | Interpretation | Next action |
| --- | --- | --- |
| Rome IV pain pattern with altered stool form/frequency; no alarm features | Supports a positive IBS diagnosis. [7][11][14] | Classify stool subtype and obtain targeted testing when indicated by diarrhea-predominant symptoms or exposure history. [11][14] |
| Unexplained iron-deficiency anemia, rectal bleeding, or recurrent bleeding | Alarm pattern; IBS alone should not be assumed. [11][14] | Evaluate for an organic gastrointestinal source, including structural and inflammatory disease. [11][14] |
| Unintentional weight loss, nocturnal symptoms, or acute unexplained symptom change | Raises concern for a non-IBS diagnosis. [14][22] | Escalate diagnostic evaluation rather than proceeding through routine empiric IBS therapy. [14][22] |
| New onset after age 45 to 50 years or first-degree family history of colorectal cancer, IBD, or celiac disease | Higher-risk presentation requiring diagnostic reassessment. [11][14] | Use history-directed investigation for colorectal, inflammatory, or celiac disease. [11][14] |

## Targeted testing for diarrhea-predominant and atypical presentations

Testing should answer a specific competing diagnosis, not serve as a routine exclusion panel.

For IBS-D or nonconstipated IBS without alarm features, obtain celiac serology with total serum IgA and tissue transglutaminase IgA. This combination identifies IgA deficiency that could make isolated tissue transglutaminase IgA testing unreliable and addresses celiac disease as a treatable mimic of chronic diarrhea and abdominal symptoms. [14]

Use serum CRP together with fecal calprotectin or fecal lactoferrin when inflammatory bowel disease is a competing diagnosis in IBS-D. A fecal calprotectin value below 100 mcg/g, in a patient without alarm features and with normal routine blood testing, identified IBS with 98% certainty in one diagnostic investigation; an elevated marker should shift evaluation toward intestinal inflammation rather than functional treatment escalation. [11][13][14]

Order a Giardia stool antigen only when exposure risk is present, including travel or immigration from endemic areas, untreated or inadequately treated water exposure, or daycare exposure. Do not use broad infectious testing as routine IBS workup in a stable, low-risk symptom pattern. [14]
- Celiac testing: total IgA plus tissue transglutaminase IgA. [14]
- Inflammation testing in IBS-D: CRP plus fecal calprotectin or fecal lactoferrin. [11][14]
- Giardia testing: stool antigen when travel, endemic exposure, unsafe water, or daycare exposure is present. [14]

### Phenotypes that should not be managed as routine IBS

Watery Bristol type 6 to 7 stools occurring primarily during waking hours, urgency, bloating, incomplete evacuation, and mucus can occur in IBS-D, but these features do not override alarm signs or abnormal inflammatory testing. In a patient with weight loss, anemia, recurrent bleeding, later-life onset, or a relevant family history, pursue the alternative diagnosis suggested by the presentation before initiating repeated IBS-directed medication trials. [14]

*Focused diagnostic tests for common IBS-D mimics and their decision implications. [11][13][14]*

| Competing diagnosis | Test | Interpretation and action |
| --- | --- | --- |
| Celiac disease | Total serum IgA and tissue transglutaminase IgA. [14] | Positive serology redirects evaluation to celiac disease rather than IBS-only management. [14] |
| Inflammatory bowel disease | CRP plus fecal calprotectin or fecal lactoferrin. [11][14] | Normal results support an IBS pathway; elevated inflammatory markers warrant investigation for intestinal inflammation. [11][14] |
| IBS versus IBD in low-risk presentation | Fecal calprotectin <100 mcg/g with no alarm features and normal routine blood tests. [13] | Reported to identify IBS with 98% certainty; interpret in the full clinical context. [13] |
| Giardiasis | Giardia stool antigen. [14] | Test when exposure risk includes endemic travel or immigration, unsafe water, or daycare contact. [14] |

## Set a symptom-directed treatment plan

Select one or two targets, define a response measure, and avoid simultaneous changes that obscure benefit.

Explain that IBS is diagnosed positively and that treatment targets symptom control rather than a proven disease-modifying therapy. Establish the dominant target—abdominal pain, diarrhea, constipation, bloating, or urgency—and track it with weekly symptom frequency and Bristol stool form. Symptoms and predominant stool pattern can change over time, so reassess the treatment target rather than assuming initial subtype is fixed. [7][11]

For global symptoms or constipation-associated symptoms, use soluble fiber such as ispaghula at 6 to 30 g/day. Soluble fiber has moderate-quality evidence in unselected IBS populations; its use is preferable to a nonspecific recommendation to increase dietary fiber without identifying fiber type. [4]

For abdominal pain, consider an antispasmodic or enteric peppermint oil as first-line pharmacologic options. Examples reported include hyoscine 20 mg three times daily and peppermint oil 200 mg three times daily. Antispasmodics can cause dry mouth, dizziness, and blurred vision; choose them cautiously when anticholinergic adverse effects are likely to limit adherence. [4][5]
- Use a dietitian-supported low-FODMAP intervention when simpler dietary measures are insufficient or when diet is a prominent symptom trigger. [4][7][22]
- Use exercise as an adjunctive nonpharmacologic option; clinical reviews identify potential symptom benefit. [7]
- Do not use a positive response to diet, fiber, or antispasmodic therapy as proof that organic disease has been excluded when alarm features or abnormal tests are present. [11][14]

### Escalation for persistent pain

When first-line pain therapy is inadequate, central neuromodulation is a second-line option; tricyclic antidepressants are preferred in the cited management guidance. In practice, select this pathway when pain remains the principal disability after bowel-habit therapy and discuss adverse-effect tradeoffs before treatment. [4]

*Initial therapies selected by dominant IBS symptom. [4][5][7]*

| Target | Reasonable initial option | Key selection issue |
| --- | --- | --- |
| Global symptoms or constipation-associated symptoms | Soluble fiber, such as ispaghula 6-30 g/day. [4] | Use soluble rather than an unspecified fiber strategy. [4] |
| Abdominal pain | Hyoscine 20 mg three times daily or peppermint oil 200 mg three times daily. [4] | Antispasmodics carry anticholinergic-type adverse effects including dry mouth, dizziness, and blurred vision. [4] |
| Diet-associated symptoms | Low-FODMAP dietary intervention, preferably with dietitian involvement when initial measures fail. [4][7] | Use a structured dietary trial rather than indiscriminate food-allergy testing. [11] |
| Persistent pain after first-line measures | Tricyclic antidepressant-based neuromodulation. [4] | Reserve for insufficient response to first-line pain therapies. [4] |

## Choose therapy by IBS-C or IBS-D phenotype

Treat constipation and diarrhea directly while maintaining surveillance for a phenotype change that suggests another diagnosis.

For IBS-C, begin with laxative therapy for constipation. If constipation remains inadequately controlled after laxatives, offer a linaclotide trial; linaclotide is reported as a strong recommendation with high-quality evidence for IBS-C. Lubiprostone is also listed as a strongly recommended IBS-C option with moderate-quality evidence. [4][19]

For IBS-D, loperamide is a first-line option for diarrhea, although evidence for efficacy is limited. For persistent nonconstipated IBS symptoms, rifaximin is listed as a strongly recommended treatment with moderate-quality evidence; eluxadoline and alosetron are listed as conditional options. Treatment selection should follow exclusion of celiac disease, inflammatory bowel disease, and exposure-related Giardia when those diagnoses remain plausible. [4][14][19]

Alosetron and ramosetron are described as among the most effective options for diarrhea-predominant IBS in the cited management review, while the ACG-based summary characterizes alosetron as conditional with low-quality evidence. This difference supports reserving 5-HT3-directed therapy for selected refractory IBS-D after individualized risk-benefit assessment rather than positioning it as routine initial treatment. [4][19]
- IBS-C not responding to laxatives: move to linaclotide rather than continuing ineffective laxative escalation indefinitely. [4]
- IBS-D with ongoing symptoms after first-line diarrhea control: consider rifaximin; evaluate eluxadoline or alosetron selectively. [19]
- IBS-M: reclassify the current predominant symptom at each treatment decision and avoid a fixed long-term label when stool pattern shifts. [7][11]

*Subtype-directed medication options supported in cited IBS management literature. [4][19]*

| Subtype and problem | Treatment sequence | Evidence or practical limitation |
| --- | --- | --- |
| IBS-C with constipation | Laxative trial first. [4] | Laxatives are used first line for constipation. [4] |
| IBS-C refractory to laxatives | Trial linaclotide. [4] | Linaclotide is listed as a strong recommendation with high-quality evidence for IBS-C. [19] |
| IBS-C requiring prescription alternative | Lubiprostone. [19] | Listed as a strong recommendation with moderate-quality evidence. [19] |
| IBS-D with diarrhea | Loperamide first line. [4] | Evidence for efficacy is described as limited. [4] |
| Persistent IBS-D or nonconstipated IBS symptoms | Rifaximin. [19] | Listed as a strong recommendation with moderate-quality evidence. [19] |
| Selected refractory IBS-D | Eluxadoline or alosetron. [19] | Both are listed as conditional options; alosetron is characterized as low-quality evidence in the ACG-based summary. [19] |

## Reassess response and identify failed-IBS pathways

Follow treatment response by prespecified symptom targets and escalate investigation when the phenotype no longer fits.

At follow-up, compare abdominal pain frequency, stool frequency, Bristol stool form, urgency, and functional impairment with baseline. Continue an intervention only when the measured target improves; when it does not, determine whether the failure reflects incorrect subtype targeting, inadequate adherence to a dietary or fiber trial, adverse effects, or an alternative diagnosis requiring renewed testing. [7][11]

Escalate beyond routine IBS management when targeted testing is abnormal, an alarm feature emerges, or symptoms become newly atypical. A low fecal calprotectin result can support an IBS pathway in a low-risk presentation, but it does not supersede bleeding, anemia, weight loss, later-life onset, or a strong family history. [11][13][14]

For persistent pain despite dietary, bowel-habit, and first-line analgesic approaches, use a neuromodulator pathway rather than repeatedly changing antidiarrheals or laxatives when pain is the main remaining symptom. For persistent IBS-C after laxatives, use linaclotide; for persistent IBS-D, consider rifaximin or a selected subtype-specific agent after revisiting celiac, inflammatory, and infectious alternatives. [4][14][19]
- Monitor each trial against a named target: pain, stool form, stool frequency, urgency, or constipation. [7][11]
- Reassess medication adverse effects, particularly dry mouth, dizziness, and blurred vision with antispasmodics. [4]
- Repeat diagnostic assessment when alarm features arise, even in a patient with an established prior IBS diagnosis. [11][14]

*Follow-up triggers that change management. [4][11][13][14][19]*

| Follow-up finding | Interpretation | Next step |
| --- | --- | --- |
| Improved target symptom and stable absence of alarm features | Current subtype-directed strategy is effective. [7][11] | Continue the effective intervention and monitor stool pattern because subtype may change over time. [7] |
| Persistent pain despite first-line measures | Pain-predominant IBS may need a neuromodulator strategy. [4] | Consider tricyclic antidepressant-based central neuromodulation. [4] |
| IBS-C persists despite laxatives | Initial constipation therapy has failed. [4] | Offer linaclotide. [4] |
| IBS-D persists despite first-line control | Consider escalation after revisiting mimics. [14][19] | Consider rifaximin; select eluxadoline or alosetron when appropriate. [19] |
| New bleeding, anemia, weight loss, nocturnal symptoms, or abnormal inflammatory testing | Presentation no longer supports routine uncomplicated IBS management. [11][14] | Pursue evaluation for organic gastrointestinal disease. [11][14] |

## References
1. Yield of Diagnostic Tests for Celiac Disease in Individuals ... — jamanetwork.com — https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1108430
2. Ethosuximide and Irritable Bowel Syndrome–Related ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2843540
3. Acupuncture for the Treatment of Diarrhea-Predominant ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799968
4. Best management of irritable bowel syndrome — fg.bmj.com — https://fg.bmj.com/content/flgastro/12/4/303.full.pdf
5. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis | The BMJ — www.bmj.com — https://www.bmj.com/content/337/bmj.a2313.full
6. Management of the multiple symptoms of irritable bowel syndrome — www.thelancet.com — https://www.thelancet.com/journals/langas/article/PIIS2468-1253(16)30116-9/abstract
7. Irritable bowel syndrome — www.bmj.com — https://www.bmj.com/content/345/bmj.e5836
8. CLINICAL REVIEW — www.bmj.com — https://www.bmj.com/content/bmj/345/bmj.e5836.full.pdf
9. British Society of Gastroenterology guidelines on the ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2021/05/24/gutjnl-2021-324598.full.pdf
10. Irritable bowel syndrome | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/nrdp201614
11. Diagnosis and treatment of irritable bowel... : Journal of the American Association of Nurse Practitioners — journals.lww.com — https://journals.lww.com/jaanp/_layouts/15/oaks.journals/downloadpdf.aspx?an=01741002-202603000-00008
12. Knowledge Does Not Translate Into Diagnostic Restraint ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/nmo.70335
13. Diagnosis and investigation of irritable bowel syndrome — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/apt.16597
14. Differential Diagnosis of Chronic Diarrhea : Journal of Clinical Gastroenterology — journals.lww.com — https://journals.lww.com/jcge/_layouts/15/oaks.journals/downloadpdf.aspx?an=00004836-202308000-00004
15. Canadian Association of Gastroenterology Clinical Practice ... — academic.oup.com — https://academic.oup.com/jcag/article/2/1/6/5290372
16. Algorithms or biomarkers in patients with lower DGBI? — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/nmo.14856
17. defined irritable bowel syndrome in the United Kingdom — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/apt.16939
18. Irritable bowel syndrome and diet | Gastroenterology Report — academic.oup.com — https://academic.oup.com/gastro/article/5/1/11/2931986
19. S688 Irritable Bowel Syndrome Therapy and Cost in Uninsured : Official journal of the American College of Gastroenterology | ACG — journals.lww.com — https://journals.lww.com/ajg/fulltext/2023/10001/s688_irritable_bowel_syndrome_therapy_and_cost_in.1044.aspx
20. Nonallergic Diseases Associated With Foods — www.jaci-inpractice.org — https://www.jaci-inpractice.org/article/S2213-2198(23)01058-9/abstract
21. Clinical study protocol — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/39/NCT05392439/Prot_SAP_000.pdf
22. Evaluate and compare the clinical efficacy of the Mediterranean ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/19/NCT05807919/Prot_SAP_000.pdf
23. Study Details | NCT06420843 | Microbiota, Metabolome and Nutrition: an 'Artificially Intelligent' Way to Personalized Nutrition | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT06420843
24. Effects of Rifaximin on Visceral Hypersensitivity in Irritable ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/66/NCT03462966/Prot_SAP_000.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.